Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
about
Antiplatelet agents for secondary prevention of ischemic strokeThe Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus IntracoronaryIntegrins: signaling, disease, and therapy.Thrombin-induced conversion of fibrinogen to fibrin results in rapid platelet trapping which is not dependent on platelet activation or GPIb.Bitistatin-functionalized fluorescent nanodiamond particles specifically bind to purified human platelet integrin receptor αIIbβ3 and activated platelets.
P2860
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
@ast
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
@en
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
@nl
type
label
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
@ast
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
@en
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
@nl
prefLabel
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
@ast
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
@en
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
@nl
P2093
P2860
P1476
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
@en
P2093
P2860
P304
P356
10.1517/13543784.9.11.2673
P407
P577
2000-11-01T00:00:00Z